would like to highlight Avant Diagnostics, Inc.
), a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
In the company’s news,
Ovarian cancer is the eighth most common form of cancer in the United States, according to the Centers for Disease Control and Prevention, and it’s the fifth leading cause of cancer deaths. This dangerous form of cancer begins as a growth of abnormal malignant cells in the ovaries before spreading to other sites within the body. Although we still don’t know exactly what causes ovarian cancers, we do know that some factors make women more likely to develop epithelial ovarian cancer during their lifetime. According to the American Cancer Society, both inherited genetic mutations and acquired genetic changes can place women at a heightened risk of developing this dangerous condition.
For women in an elevated risk category for ovarian cancer, regular screening and, if necessary, early detection can play a major role in overall health and wellbeing. If diagnosed in its early stages, ovarian cancer is an extremely survivability illness. When discovered in stage one, approximately 92 percent of ovarian cancer cases surpass the recorded five-year survival milestone. Despite this statistic, the average five-year survival rate for ovarian cancer is just 44 percent. This is because only 15 percent of ovarian cancers are currently diagnosed during stage one, according to Healthline.
Avant Diagnostics, Inc. (OTCQB: AVDX) is on a mission to improve the survivability of ovarian cancer by giving women access to more effective early detection technology. The company’s pre-symptomatic ovarian cancer screening test, OvaDx®, is a leading breakthrough in the field of ovarian cancer diagnostics. OvaDx is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. In clinical research, the test has indicated high sensitivity and specificity for all types and stages of ovarian cancer.
Following FDA approval, Avant intends to offer OvaDx as an elective test for women in the elevated risk category for ovarian cancer, as well as those seeking greater wellness. As the market’s first large panel screening test for ovarian cancer, OvaDx is expected to greatly improve the early diagnosis rate of ovarian cancer and, as a result, advance the survivability of this deadly disease.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.